Covaxx

Vaxxinity is a clinical-stage biotechnology company focused on developing a new class of immunotherapeutic vaccines for chronic and infectious diseases. The company was formed in 2021 through the merger of COVAXX and United Neuroscience, combining expertise in COVID-19 vaccine development and neurodegenerative disease research. Vaxxinity utilizes a proprietary synthetic peptide platform designed to stimulate the immune system to produce antibodies against specific endogenous or exogenous targets. Its lead programs include UB-612, a multitope vaccine for COVID-19, and several candidates targeting Alzheimer's and Parkinson's diseases. The company aims to provide cost-effective, scalable, and accessible biologics to global populations.